or Try an Advanced Search...

    Technical Analysis for SPRB - Spruce Biosciences, Inc.

    Grade Last Price % Change Price Change
    F 0.53 2.55% 0.01
    SPRB closed up 2.55 percent on Monday, July 1, 2024, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical SPRB trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Inside Day Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Calm After Storm Range Contraction 2.55%
    Stochastic Reached Oversold Weakness 2.55%
    Wide Bands Range Expansion 2.55%
    Down 3 Days in a Row Weakness 2.55%
    Oversold Stochastic Weakness 2.55%
    Older End-of-Day Signals for SPRB ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 6 hours ago
    Possible Inside Day about 6 hours ago
    2x Volume Pace about 9 hours ago
    1.5x Volume Pace about 9 hours ago
    Up 3% about 10 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    SPRB Chart by TradingView
    Basic chart:

    Profile

    Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company develops tildacerfont, an non-steroidal therapy, which is in Phase IIb clinical trial for adult patients with classic congenital adrenal hyperplasia (CAH) and in Phase II clinical trial in children with classic CAH. It is also developing tildacerfont for females with polycystic ovary syndrome. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was founded in 2014 and is headquartered in Daly City, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Hyperplasia Endocrine Disorders Congenital Adrenal Hyperplasia Neurocrine Biosciences

    Is SPRB a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 24 Pipeline Moves: Approval prospects for BioTissue’s diabetic foot ulcer drug up after Phase III completion
    Jun 6 Spruce Biosciences Recognized as a Bay Area Best Place to Work
    Jun 4 Nano-Cap Spruce Biosciences Collaborates With HMNC Brain Health To Develop Treatment for Major Depressive Disorder
    Jun 4 Spruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder (MDD)
    Jun 3 Spruce Biosciences Presented Phase 2 POWER Study Results of Tildacerfont for the Treatment of Polycystic Ovary Syndrome at ENDO 2024
    May 23 Spruce Biosciences to Participate in the Jefferies Global Healthcare Conference
    May 22 Spruce Biosciences Announces Poster Presentations at the 2024 Annual Meeting of the Endocrine Society
    May 13 Spruce Biosciences GAAP EPS of -$0.28 beats by $0.02, revenue of $2M beats by $0.84M
    May 13 Spruce Biosciences, Inc. (SPRB) Reports Q1 Loss, Tops Revenue Estimates
    May 13 Spruce Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
    See more SPRB news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 5.95
    52 Week Low 0.503
    Average Volume 527,969
    200-Day Moving Average 1.89
    50-Day Moving Average 0.70
    20-Day Moving Average 0.62
    10-Day Moving Average 0.56
    Average True Range 0.04
    RSI (14) 31.51
    ADX 43.31
    +DI 10.34
    -DI 36.21
    Chandelier Exit (Long, 3 ATRs) 0.63
    Chandelier Exit (Short, 3 ATRs) 0.62
    Upper Bollinger Bands 0.77
    Lower Bollinger Band 0.47
    Percent B (%b) 0.2
    BandWidth 47.23
    MACD Line -0.07
    MACD Signal Line -0.06
    MACD Histogram -0.0019
    Fundamentals Value
    Market Cap 21.61 Million
    Num Shares 40.7 Million
    EPS -1.48
    Price-to-Earnings (P/E) Ratio -0.36
    Price-to-Sales 24.67
    Price-to-Book 1.90
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.56
    Resistance 3 (R3) 0.56 0.55 0.55
    Resistance 2 (R2) 0.55 0.54 0.55 0.55
    Resistance 1 (R1) 0.54 0.54 0.54 0.54 0.55
    Pivot Point 0.53 0.53 0.53 0.53 0.53
    Support 1 (S1) 0.52 0.52 0.53 0.52 0.51
    Support 2 (S2) 0.51 0.52 0.51 0.51
    Support 3 (S3) 0.50 0.51 0.51
    Support 4 (S4) 0.50